Results
415 adult patients, mean age 36.6 years, 61.4% female, 36% asthmatic
were included. 65.3% of patients experienced possibly-related adverse
events (AEs). These mostly mild (67%) AEs comprised: oral allergic
reactions (58.6%), respiratory (12.4%) and gastrointestinal symptoms
(9.4%).
60 (14.5%) patients stopped due to AEs and 76 (18.3%) for non-AE
reasons. Mean CARAT scores improved clinically significant by 6 points
and symptomatic medication use decreased from 96.1% to 77.4%. 74.5%
of patients tolerated the treatment well. Most patients were compliant
(>86.5%) and patients (62.4 %) and investigators (69.4%)
were satisfied with treatment.